Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age60+
SponsorGerman University in Cairo

About this trial

This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.

Eligibility criteria

Qualifiers

Age >60 years

Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)

Disqualifiers

Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis)

Patients with history of L-arginine intolerance or allergy

Patients with asthma

Patients who recently had an acute myocardial infarction

Trial design

Treatments tested in this trial

  • L-Arginine
  • Placebo

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators